Sana’s HIP-Modified Islet Cells Persist and Function in Type 1 Diabetes Patient

Sana's HIP-modified pancreatic islet cells, transplanted without immunosuppression, persisted and functioned in a patient with type 1 diabetes. Six-month follow-up results demonstrated that the cells were safe, well-tolerated, and produced insulin. Sana is developing SC451, a HIP-modified stem cell-derived therapy, as a one-time treatment for type 1 diabetes with the goal of normal blood glucose levels without insulin or immunosuppression. The FDA INTERACT meeting increased confidence in moving forward with GMP master cell bank production for SC451.